ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
68,192.08
0.69%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immunocore Holdings PLC (IMCR)

  7. Immunocore Holdings PLC (IMCR) News

Immunocore (IMCR)

Immunocore Holdings PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMCR
DateTimeSourceHeadlineSymbolCompany
01/06/202413:00GlobeNewswire Inc.Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseNASDAQ:IMCRImmunocore Holdings PLC
31/05/202421:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
31/05/202421:05GlobeNewswire Inc.Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024NASDAQ:IMCRImmunocore Holdings PLC
30/05/202421:00GlobeNewswire Inc.Immunocore to present at the Jefferies Global Healthcare ConferenceNASDAQ:IMCRImmunocore Holdings PLC
29/05/202412:00GlobeNewswire Inc.Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanomaNASDAQ:IMCRImmunocore Holdings PLC
28/05/202421:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
28/05/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
28/05/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
28/05/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
28/05/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
23/05/202421:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
08/05/202412:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
08/05/202412:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMCRImmunocore Holdings PLC
08/05/202412:00GlobeNewswire Inc.Immunocore reports first quarter financial results and provides a business updateNASDAQ:IMCRImmunocore Holdings PLC
24/04/202415:00GlobeNewswire Inc.Immunocore announces upcoming presentation and posters at ASCO 2024NASDAQ:IMCRImmunocore Holdings PLC
04/04/202421:00GlobeNewswire Inc.Immunocore to present at upcoming investor conferencesNASDAQ:IMCRImmunocore Holdings PLC
05/03/202421:30GlobeNewswire Inc.Immunocore presented two posters at CROI 2024NASDAQ:IMCRImmunocore Holdings PLC
01/03/202412:00GlobeNewswire Inc.Immunocore to present at upcoming investor conferencesNASDAQ:IMCRImmunocore Holdings PLC
28/02/202421:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
28/02/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
28/02/202412:34GlobeNewswire Inc.Immunocore reports fourth quarter and full year 2023 financial results and provides a business updateNASDAQ:IMCRImmunocore Holdings PLC
28/02/202412:33Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMCRImmunocore Holdings PLC
26/02/202423:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IMCRImmunocore Holdings PLC
22/02/202412:00GlobeNewswire Inc.Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trialNASDAQ:IMCRImmunocore Holdings PLC
21/02/202421:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
21/02/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
21/02/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
21/02/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
21/02/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
21/02/202412:00GlobeNewswire Inc.Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024NASDAQ:IMCRImmunocore Holdings PLC
 Showing the most relevant articles for your search:NASDAQ:IMCR

Your Recent History

NYSE
CHS
Chicos FAS
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved